BACKGROUND AND PURPOSE: The insulin-like growth factors (IGF) are synthesized in the brain and are involved in fetal brain development. An increased expression of @entity442 and @entity5100 occurs in cerebral regions with @entity528 after experimental @entity130 . Furthermore, the expression of mRNAs coding for @entity442 and the binding proteins @entity10513 and @entity2301 is augmented in response to unilateral @entity63 in animal models. The secretory dynamics of @entity442 in @entity1 @entity2806 have not yet been investigated. METHODS: Plasma @entity442 and @entity2301 were measured sequentially in 20 @entity1 with acute @entity385 (within 24 hours and 3, 5, and 10 days thereafter). For analysis the @entity1 were assigned to three groups according to the diameter of the @entity1188 area as measured on CT scan: small (< 1.5 cm), moderate (> or = 1.5 cm and < or = 5 cm), and large (> 5 cm). Eight age-matched @entity1 with nonvascular, neurological illnesses served as controls. RESULTS: Plasma @entity442 and @entity2301 plasma concentrations after @entity2806 were strikingly lower than those in control subjects and healthy individuals reported in the literature. Plasma @entity442 levels in @entity1 with large @entity1188 were significantly statistically lower than those in control subjects (P < .05), and plasma @entity2301 levels were significantly lower than those in control subjects on days 5 and 10. CONCLUSIONS: @entity442 and @entity2301 plasma levels are decreased in @entity1 after @entity2806 . After acute @entity385 , increased demand for growth factors, altered tissue distribution, and accelerated metabolic clearance rate or central inhibition of the @entity10759 may contribute to these low plasma concentrations. Growth factors such as @entity442 and @entity2301 may play an important role in the pathophysiology of @entity2806 , and growth factors may have a considerable effect on future therapeutic regimens.

Plasma insulin-like growth factor I and @entity2301 levels in @entity1 with acute cerebral XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia', 'acute cerebral ischemia'] @entity2301 :: ('3486', 'Gene') :: ['IGFBP-3'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity10759 :: ('MESH:D049912', 'Disease') :: ['somatotrophic axis'] @entity10513 :: ('3485', 'Gene') :: ['IGFBP-2'] @entity442 :: ('3479', 'Gene') :: ['IGF-I'] @entity5100 :: ('3481', 'Gene') :: ['IGF-II'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct', 'infarcts'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage'] @entity130 :: ('MESH:D014947', 'Disease') :: ['hypoxic injury'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity63 :: (MESH:D007511,Disease) :: ['ischemic injury']
